TG Therapeutics begins Phase II trial of TGR-1202 and ibrutinib combination to treat DLBCL

US-based biopharmaceutical company TG Therapeutics has begun its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news